Trial Profile
Post marketing surveillance (PMS) in Japan for soft tissue sarcoma (STS) patients treated with pazopanib
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 20 Jan 2016 New trial record